- Home
- HEPS vs ABUS Comparison
HEPS vs ABUS Comparison
Compare HEPS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- ABUS
- Stock Information
- Founded
- HEPS 2000
- ABUS 2005
- Country
- HEPS Turkey
- ABUS United States
- Employees
- HEPS N/A
- ABUS N/A
- Industry
- HEPS Catalog/Specialty Distribution
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- ABUS Health Care
- Exchange
- HEPS Nasdaq
- ABUS Nasdaq
- Market Cap
- HEPS 811.7M
- ABUS 672.1M
- IPO Year
- HEPS 2021
- ABUS N/A
- Fundamental
- Price
- HEPS $2.66
- ABUS $3.36
- Analyst Decision
- HEPS
- ABUS Strong Buy
- Analyst Count
- HEPS 0
- ABUS 4
- Target Price
- HEPS N/A
- ABUS $5.50
- AVG Volume (30 Days)
- HEPS 348.8K
- ABUS 843.8K
- Earning Date
- HEPS 06-12-2025
- ABUS 05-14-2025
- Dividend Yield
- HEPS N/A
- ABUS N/A
- EPS Growth
- HEPS N/A
- ABUS N/A
- EPS
- HEPS N/A
- ABUS N/A
- Revenue
- HEPS $1,471,066,066.00
- ABUS $6,403,000.00
- Revenue This Year
- HEPS $22.80
- ABUS $14.57
- Revenue Next Year
- HEPS $25.49
- ABUS $15.84
- P/E Ratio
- HEPS N/A
- ABUS N/A
- Revenue Growth
- HEPS 42.87
- ABUS N/A
- 52 Week Low
- HEPS $1.71
- ABUS $2.71
- 52 Week High
- HEPS $4.05
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- HEPS 45.42
- ABUS 53.55
- Support Level
- HEPS $2.56
- ABUS $3.04
- Resistance Level
- HEPS $2.90
- ABUS $3.54
- Average True Range (ATR)
- HEPS 0.11
- ABUS 0.14
- MACD
- HEPS 0.00
- ABUS 0.02
- Stochastic Oscillator
- HEPS 29.85
- ABUS 70.00
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.